This brief accredited CME publication examines the rationale and current evidence for the transplantation of kidneys from hepatitis C virus (HCV)–positive donors into HCV-negative recipients. In particular, it explores changes in the characteristics of the donor pool due to the ongoing opioid crisis and reviews short- to intermediate-term outcomes from ongoing prospective trials. The efficacy and safety of treatment with direct-acting antiviral (DAA) agents is also discussed. Additionally, this publication features a short video clip of expert perspectives on transplanting HCV-positive kidneys into HCV-negative recipients before and after the emergence of DAAs and briefly explores outcomes from the EXPANDER-1 and THINKER-1 prospective trials.
Scott L. Sanoff, MD, MPH
Assistant Professor of Medicine
Division of Nephrology
Duke Transplant Center